<?xml version="1.0" encoding="UTF-8"?>
<p>MOA: as mentioned above, excess stimulation of the immune response leads to an exaggerated release of IL-6, which is responsible for a series of events resulting in organ damage and worsening of the overall clinical condition of the patient. Tocilizumab inhibits IL-6-mediated signaling by binding to both soluble and membrane-bound IL-6R, ultimately causing effective downregulation of the immune system [
 <xref rid="REF36" ref-type="bibr">36</xref>].
</p>
